New insight into how tissue factor allosterically regulates Factor VIIa

Trends in Cardiovascular Medicine

Volumn 12, Issue 1, 2002, Pages 19-26

  Eigenbrot, Charles ^a   Kirchhofer, Daniel ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN;

ALLOSTERISM; ATHEROSCLEROSIS; BLOOD CLOTTING; ENZYME ACTIVITY; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; REVIEW; THROMBOCYTE ACTIVATION; THROMBOSIS;

FACTOR VIIA; HUMANS; PROTEIN STRUCTURE, TERTIARY; SECRETORY VESICLES; SERINE ENDOPEPTIDASES; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOPLASTIN;

EID: 0036139935     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(01)00139-6     Document Type: Review

References (79)

1. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes
2. Molecular analysis of Polish patients with factor VII deficiency
3. Fibrin-rich and platelet-rich thrombus formation on neointima; recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta
4. Factor VII binding to tissue factor in reconstituted phospholipid vesicles; induction of cooperativity by phosphatidylserine
5. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques
6. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor
7. Structural design and molecular evolution of a cytokine receptor superfamily
8. 334Ser → Pro)
9. Molecular defects in CRM+ factor VII deficiencies; modelling of missense mutations in the catalytic domain of FVII
10. Kinetics of human factor VII activation
11. Synthetic substrates for human factor VIIa and factor VIIa-tissue factor
12. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa
13. Coagulation factors VIIa and Xa induce cell signalling leading to up-regulation of the egr-1 gene
14. Inherited factor VII deficiency; molecular genetics and pathophysiology
15. How the protease thrombin talks to cells
16. Peptide exosite inhibitors of factor VIIa as anticoagulants
17. Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa
18. Active site modification of factor VIIa affects interactions of the protease domain with tissue factor
19. Influence of cofactor binding and active site occupancy on the conformation of the macromolecular substrate exosite of factor VIIa
20. The factor VII zymogen structure reveals re-registration of β-strands during activation
21. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation
22. Identification of the factor VIIa binding site on tissue factor by homologous loop swap and alanine scanning mutagenesis
23. Blood-borne tissue factor; another view of thrombosis
24. Recombinant human, active site-blocked factor VIIa reduces infarct size and no-reflow phenomenon in rabbits
25. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway
26. Crystal structure of the extracellular region of human tissue factor
27. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa
28. Molecular mechanism of tissue factor-mediated acceleration of factor VIIa activity
29. Conformation of factor VIIa stabilized by a labile disulfide bond (Cys-310-Cys-329) in the protease domain is essential for interaction with tissue factor
30. Identification of regions of bovine factor VII essential for binding to tissue factor
31. Tissue factor potentiates the factor VIIa-catalyzed hydrolysis of an ester substrate
32. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function
33. Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig
34. 1-161) in experimental venous thrombosis-a comparison with low molecular weight heparin
35. Structural basis of the activation and action of trypsin
36. Structure of a serpin-protease complex shows inhibition by deformation
37. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model
38. Tissue factor expression on macrophages in coronary plaques in patients with un-stable angina
39. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent
40. Tissue factor residue Asp44 regulates catalytic function of the bound proteinase factor VIIa
41. Crystal structure of active site-inhibited human coagulation factor VIIa (des-Gla)
42. The tissue factor region that interacts with substrates factor IX and factor X
43. A dose-response study of the factor VIIa/tissue factor inhibitor rNAPc2 in the prevention of postoperative venous thrombosis in patients undergoing total knee arthroplasty
44. Regulation of the thrombotic potential of atheroma
45. Molecular and clinical aspects of factor VII deficiency
46. Identification of active tissue factor in human coronary atheroma
47. 304 → Trp)
48. The location of the active site of blood coagulation factor VIIa above the membrane surface and its reorientation upon association with tissue factor
49. Evidence that translocation of the proteinase precedes its acylation in the serpin inhibition pathway
50. Macrophages, smooth muscle cells, and tissue factor in unstable angina
51. Structure of the extracellular domain of human tissue factor; location of the factor VIIa binding site
52. Initiation of the extrinsic pathway of blood coagulation; evidence for the tissue factor dependent autoactivation of human coagulation factor VII
53. Tissue factor and hemostasis
54. Importance of substrate composition, pH and other variables on tissue factor enhancement of factor VIIa activity
55. Factor VII autoactivation proceeds via interaction of distinct protease-cofactor and zymogen-cofactor complexes. Implications of a two-dimensional enzyme kinetic mechanism
56. Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa
57. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries
58. Autoactivation of human recombinant coagulation factor VII
59. Substitution of aspartic acid for methionine-306 in factor VIIa abolishes the allosteric linkage between the active site and the binding interface with tissue factor
60. Tissue factor-dependent factor VIIa signalling
61. 225 in the cofactor-mediated, allosteric regulation of the serine protease coagulation factor VIIa
62. 156 contributes to the labile enzyme conformation of coagulation factor VIIa
63. Structure of human factor VIIa and its implications for the triggering of blood coagulation
64. Activation of factor VII bound to tissue factor; a key early step in the tissue factor pathway of coagulation
65. Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty
66. Lysine residues 165 and 166 are essential for the cofactor function of tissue factor
67. The interaction of activated factor VII with tissue factor; insight into the mechanism of cofactor-mediated activation of activated factor VII
68. Cofactor residues lysine 165 and 166 are critical for protein substrate recognition by the tissue factor-factor VIIa protease complex
69. Tissue factor signaling
70. Manipulation of the membrane binding site of vitamin K-dependent proteins; enhanced biological function of human factor VII
71. Regulation of the catalytic function of coagulation factor VIIa by a conformational linkage of surface residue Glu 154 to the active site
72. Factor VIIa modified in the 170 loop shows enhanced catalytic activity but does not change the zymogen-like property
73. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor
74. Two novel mutations causing factor VII deficiency
75. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody
76. Human factor VIIa and its complex with soluble tissue factor; evaluation of asymmetry and conformational dynamics by ultracentrifugation and fluorescence anisotropy decay methods
77. Cellular effects of initiation of the extrinsic pathway of blood coagulation
78. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
79. Structure of extracellular tissue factor complexed with Factor VIIa inhibited with a BPTI mutant